HIV/AIDS Opportunistic Infection
Oral CMV therapy superior to intravenous treatment
Published in TB and Outbreaks Week, April 27th, 2004
In a recent study from the United States, the putative "[c]ost advantages of the oral route of drug therapy administration over the intravenous route" for managing CMV disease were investigated.
"The overall costs usually are lower for the oral route of administration than for the intravenous route, although the cost to the patient depends on insurance coverage," reported K.T. Somerville and coauthors at the University of Utah Hospital. "Other advantages of the oral route include greater safety and convenience, which may improve patient adherence and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Drug Development
Indazole-derived SAH/MTA nucleosidase inhibitors have antimicrobial activity - Nosocomial Infection
Antimicrobial resistance on the rise in American hospitals - SARS Diagnostics
Novel real-time PCR assay enhances detection of SARS coronovirus - Tuberculosis Epidemiology
Genetic distance useful as measure of ongoing TB transmission - Anthrax
Adefovir selectively inhibits factor key to anthrax pathogenesis - Anti-Infectives
Ciprofloxacin can prevent infection in pediatric cancer patients - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
